

3330 Cumberland Blvd
Suite 650
Atlanta, GA 30339

September 15, 2025

RE: Invitation for 2026 GASCO Corporate Partnership

To Our Colleagues in the Georgia Cancer Care Community:

On behalf of the Georgia Society of Clinical Oncology (GASCO), we thank you for your past support of our programs and invite you to continue your supporting Corporate Partnership with GASCO for 2026. The agreement year is from January 1, 2026, through December 31, 2026.

GASCO values our Corporate Partnerships as your financial and professional collaborations over the years have allowed GASCO to build a solid reputation within the cancer care community as one of the top organizations of its kind in the country. We are recognized as an innovative and effective organization with a membership that represents the majority of cancer specialists in both academic and community settings in Georgia. GASCO's membership includes medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, Advance Practice Providers, oncology pharmacists and nurses and other administrative support professionals. GASCO's Administrators' Association and Cancer Patient Navigators of Georgia Association ensure that GASCO can be responsive to the clinical and economic needs of the practices and their patients.

A touchstone of our mission is GASCO's commitment to innovation, collaboration, education, and communication in serving the cancer care community. Our Board of Directors represents key members of the academic and major community hospital systems in Georgia. Many are nationally recognized and also serve in important roles within organizations involved with cancer research. We continue to develop innovative programs and projects in conjunction with the American Society of Clinical Oncology (ASCO®), the Georgia Center for Oncology Research and Education (Georgia CORE), the Winship Cancer Institute of Emory University, Augusta University, Morehouse School of Medicine, the Association of Oncology Nurse Navigators (AONN), and the Georgia Association of Pathologists (GAP).

Our educational collaborations with Georgia CORE and the state medical schools are aimed toward providing less duplication on content while allowing each part of the team to contribute based on their core competencies. This has resulted in well-attended and

Board of Directors

Chirag Jani, MD
President

•

Ticiana Leal, MD
Vice-President, President-Elect
Secretary/Treasurer

•

Gregory Harris, DO
Secretary/Treasurer

Sharad Ghamande
Immediate Past President

•

Bradley C. Carthon, MD, PhD
Melissa Dillmon, MD, FASCO
John French, MD
Crain Garrot, MD

Christopher Hagenstad, MD
Anand Jillella, MD

Petros Nikolidakos, MD

Samantha Shams, MD

Alison Spellman, MD

Srividya Srinivasamaharaj, MD

GASCO Officers

Peter F. Lyle, Sr.
Executive Director

•

Karen M. Beard
Director

clinically robust meetings for all our constituents as well as success in improving access to clinical trials and translational oncology fields. Our Advocacy work with the Georgia State Legislature and national cancer centric organizations, such as ASCO® and the American Cancer Society have led to important legislation related to patient care access and provided templates for other state oncology societies to use to affect change in their states.

In 2026, we are planning educational offerings related to new preventive and therapeutic advancements in cancer care. Our 2025 educational programs continued to be highly rated by attendees and have been of high value to our Corporate Partners. In fact, we had a record attendance at our 2025 GASCO Annual Meeting and Licensed Best of ASCO®.

Plans for 2026 meetings with continuing education credits include, but may not be limited to:

- March 6-8, 2026 – GASCO Annual Board Retreat, the Ritz-Carlton Reynolds Lake Oconee, Greensboro, Georgia (*attendance by invitation, Platinum and Level I Corporate Partners only*).
- August 21 & 22, 2026 - GASCO's 2026 Annual Meeting and Best of ASCO®, including Administrators' Association & Business of Oncology Meeting - The Hotel at Avalon, Alpharetta, Georgia.
- October or November 2026 – GASCO Fall Meeting. Planning is in the initial stages. Venue and date to be determined; precision medicine/GAP track/other.

Attached is a document listing the cost and benefits for each level of GASCO Corporate Partnership and a comparative Chart of Benefits.

Please Note: GASCO has developed a membership program that will be launched and distributed at the end of 2025, to allow participation in our clinical programs for your Corporate Medical Affairs Executives, Managers, and Medical Science Liaisons. This membership offering is separate of your Corporate Partnership for your marketing representatives and is not interchangeable. Medical Affairs/Medical Science Liaisons will not be able to exhibit at GASCO meetings and cannot attend GASCO meetings using any unassigned passes available under your Corporate Partnership.

The enclosed Corporate Partnership Commitment Form must be returned to me by December 31, 2025. Annual funding for Platinum through Level III Corporate Partners is due no later than January 31, 2026. GASCO will accept pre-payments from Level IV Corporate Partners (meeting-by-meeting basis) to reserve an exhibit table at GASCO's 2026 Annual Meeting and Best of ASCO® until January 31, 2026 on a first come, first serve basis. After January 31st, prepayments will be accepted while there is still exhibit space available.

We hope that this letter provides you with a picture of why GASCO brings high value to corporate collaborations not common in other state oncology societies. We look forward to working with you to continue the positive trajectory of service to cancer patients.

We appreciate your past support and hope to continue a mutually beneficial relationship. If you have any questions or if I can be of assistance to you, I can be reached at (770) 951-1018, option 1, or by e-mail at pflsr@medicalmanagement.com.

Sincerely,



Peter F. Lyle, Sr.
Executive Director

PFL:amc

cc: Karen M. Beard, Director

Attachments: 2026 Corporate Partnership Levels
2026 Comparative Benefits Chart
2026 Corporate Partnership Commitment Form
GASCO W-9 Form (Tax ID No. 58-1752866 | 501(c)(6) Non-profit)